Cancer Research UK and Cancer Research Technology collaborate with TYG oncology

7 November 2016 (Last Updated November 7th, 2016 18:30)

Cancer Research UK and Cancer Research Technology (CRT), the charity’s commercial arm, have signed an agreement with TYG oncology (TYG) to take its TYG100, a new antigen-specific, active checkpoint control cancer vaccine, into clinical trials involving cancer patients with advanced solid tumours.

Cancer Research UK and Cancer Research Technology (CRT), the charity’s commercial arm, have signed an agreement with TYG oncology (TYG) to take its TYG100, a new antigen-specific, active checkpoint control cancer vaccine, into clinical trials involving cancer patients with advanced solid tumours.

TYG100 is a new treatment using a patient’s own immune system to target hormones that encourage the growth and spread of solid tumours.

This vaccine works by triggering the production of antibodies that particularly target two members of the gastrin hormone family, which fuel tumour growth.

As per the agreement, Cancer Research UK and TYG will share the cost of the process development and production of TYG100 for the clinic.

To be sponsored and managed by Cancer Research UK’s Centre for Drug Development (CDD), the Phase I clinical trial of TYG100 in cancer patients with advanced solid tumours will analyse evaluate drug safety and toxicity.

It will take place across the Experimental Cancer Medicine Centres (ECMC) network, a nationwide initiative funded by Cancer Research UK and the country's four health departments.

This collaboration is a part of Cancer Research UK’s Clinical Development Partnership (CPD) scheme. At the end of the trial, TYG oncology will have the option to either retain rights to the new treatment or transfer them to Cancer Research UK to continue development through a new partner.

TYG oncology president Fred Jacobs said: “We are very pleased to be working in partnership with the clinical experience and expertise from Cancer Research UK to advance TYG100.

"It’s a very promising area of research and we’re excited to be working with TYG oncology to take this to the next stage."

“Cancer Research UK’s sponsorship of the Phase I clinical trial is a significant technical and financial validation of our novel therapeutic vaccine. TYG100 will be attacking some of the most difficult and deadliest solid tumours, including pancreatic and gastro-oesophageal cancers.”

Cancer Research UK’s director of drug development Dr Nigel Blackburn said: “We hope that next-generation cancer vaccines like this one will build on the widespread success of existing hormonal treatments, such as those targeting oestrogen in breast cancer and testosterone in prostate cancer.

“It’s a very promising area of research and we’re excited to be working with TYG oncology to take this to the next stage.”

“Our Clinical Development Partnerships are a novel approach that allows companies to benefit from Cancer Research UK’s extensive drug development resources in a way that is mutually beneficial and that ultimately helps new treatments reach patients more quickly.”


Image: Cancer Research UK and Cancer Research Technology collaborate with TYG oncology to develop a cancer vaccine. Photo: Courtesy of Cancer Research UK